Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (40345949) | ||||||||||||
| Authors | d'Amore F, Federico M, de Leval L, Ellin F, Hermine O, Kim WS, Lemonnier F, Vermaat JSP, Wulf G, Buske C, Dreyling M, Jerkeman M, ESMO Guidelines Committees. Electronic address: clinicalguidelines@esmo.org, EHA Guidelines Committees. Electronic address: guidelines@ehaweb.org | ||||||||||||
| Title | Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | anaplastic large cell lymphoma | sensitive | Ceritinib | Guideline | Actionable | Zykadia (ceritinib) is included in guidelines for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (PMID: 40345949; ESMO.org). | detail... 40345949 |
| ALK rearrange | anaplastic large cell lymphoma | sensitive | Crizotinib | Guideline | Actionable | Xalkori (crizotinib) is included in guidelines for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (PMID: 40345949; ESMO.org). | detail... 40345949 |
| ALK rearrange | anaplastic large cell lymphoma | sensitive | Alectinib | Guideline | Actionable | Alecensa (alectinib) is included in guidelines for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (PMID: 40345949; ESMO.org). | detail... 40345949 |
| ALK rearrange | anaplastic large cell lymphoma | sensitive | Brigatinib | Guideline | Actionable | Alunbrig (brigatinib) is included in guidelines for patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma (PMID: 40345949; ESMO.org). | detail... 40345949 |